Cargando…

Sitagliptin: Is It Effective in Routine Clinical Practice?

Aim. The present study was conducted to determine the glycaemic effects of sitagliptin in type 2 diabetes patients. Methods. Data was collected from patient medical records of a major teaching hospital in Malaysia, from 2009 to 2012. Glycated hemoglobin (HbA(1c)) values prior to and up to 12 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan Dallumal, Rita, Chua, Siew Siang, Wu, David Bin-Chia, Vethakkan, Shireene Ratna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451333/
https://www.ncbi.nlm.nih.gov/pubmed/26089904
http://dx.doi.org/10.1155/2015/950571
_version_ 1782374122544693248
author Mohan Dallumal, Rita
Chua, Siew Siang
Wu, David Bin-Chia
Vethakkan, Shireene Ratna
author_facet Mohan Dallumal, Rita
Chua, Siew Siang
Wu, David Bin-Chia
Vethakkan, Shireene Ratna
author_sort Mohan Dallumal, Rita
collection PubMed
description Aim. The present study was conducted to determine the glycaemic effects of sitagliptin in type 2 diabetes patients. Methods. Data was collected from patient medical records of a major teaching hospital in Malaysia, from 2009 to 2012. Glycated hemoglobin (HbA(1c)) values prior to and up to 12 months after the initiation of sitagliptin were analysed. The change in HbA(1c) values was accounted for based on a generalized linear model generated using the Generalized Estimating Equations (GEE) method. Results and Discussion. Of the 457 patients, 53.6% were elderly and 81.4% were overweight. The mean HbA(1c) (standard deviation) before initiation of sitagliptin was 8.5 (1.4)%. This dropped to 7.7 (1.4)%, 3 to 6 months after initiation of sitagliptin, with a mean difference of 0.8% (95% confidence interval (CI): 0.7–1.0; P < 0.001). However, this value increased to 8.0 (1.7)% after 7 to 12 months on sitagliptin (P = 0.002) with a mean difference from baseline of 0.6% (95% CI: 0.4–0.7; P < 0.001). Conclusion. In routine clinical practice, sitagliptin produces a significant reduction in mean HbA(1c) (0.8%) within the first 6 months of use which corresponds to efficacy data obtained in controlled clinical trials. However, this reduction was lesser, 7 to 12 month later.
format Online
Article
Text
id pubmed-4451333
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44513332015-06-18 Sitagliptin: Is It Effective in Routine Clinical Practice? Mohan Dallumal, Rita Chua, Siew Siang Wu, David Bin-Chia Vethakkan, Shireene Ratna Int J Endocrinol Research Article Aim. The present study was conducted to determine the glycaemic effects of sitagliptin in type 2 diabetes patients. Methods. Data was collected from patient medical records of a major teaching hospital in Malaysia, from 2009 to 2012. Glycated hemoglobin (HbA(1c)) values prior to and up to 12 months after the initiation of sitagliptin were analysed. The change in HbA(1c) values was accounted for based on a generalized linear model generated using the Generalized Estimating Equations (GEE) method. Results and Discussion. Of the 457 patients, 53.6% were elderly and 81.4% were overweight. The mean HbA(1c) (standard deviation) before initiation of sitagliptin was 8.5 (1.4)%. This dropped to 7.7 (1.4)%, 3 to 6 months after initiation of sitagliptin, with a mean difference of 0.8% (95% confidence interval (CI): 0.7–1.0; P < 0.001). However, this value increased to 8.0 (1.7)% after 7 to 12 months on sitagliptin (P = 0.002) with a mean difference from baseline of 0.6% (95% CI: 0.4–0.7; P < 0.001). Conclusion. In routine clinical practice, sitagliptin produces a significant reduction in mean HbA(1c) (0.8%) within the first 6 months of use which corresponds to efficacy data obtained in controlled clinical trials. However, this reduction was lesser, 7 to 12 month later. Hindawi Publishing Corporation 2015 2015-05-18 /pmc/articles/PMC4451333/ /pubmed/26089904 http://dx.doi.org/10.1155/2015/950571 Text en Copyright © 2015 Rita Mohan Dallumal et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mohan Dallumal, Rita
Chua, Siew Siang
Wu, David Bin-Chia
Vethakkan, Shireene Ratna
Sitagliptin: Is It Effective in Routine Clinical Practice?
title Sitagliptin: Is It Effective in Routine Clinical Practice?
title_full Sitagliptin: Is It Effective in Routine Clinical Practice?
title_fullStr Sitagliptin: Is It Effective in Routine Clinical Practice?
title_full_unstemmed Sitagliptin: Is It Effective in Routine Clinical Practice?
title_short Sitagliptin: Is It Effective in Routine Clinical Practice?
title_sort sitagliptin: is it effective in routine clinical practice?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451333/
https://www.ncbi.nlm.nih.gov/pubmed/26089904
http://dx.doi.org/10.1155/2015/950571
work_keys_str_mv AT mohandallumalrita sitagliptinisiteffectiveinroutineclinicalpractice
AT chuasiewsiang sitagliptinisiteffectiveinroutineclinicalpractice
AT wudavidbinchia sitagliptinisiteffectiveinroutineclinicalpractice
AT vethakkanshireeneratna sitagliptinisiteffectiveinroutineclinicalpractice